Search results for PCSK6

Showing 8 results out of 8

×

Species

Types

Compartments

Search properties

Species

Types

Compartments

Search properties

Protein (4 results from a total of 4)

Identifier: R-HSA-1181107
Species: Homo sapiens
Compartment: extracellular region
Primary external reference: UniProt: PCSK6: P29122
Identifier: R-HSA-8849792
Species: Homo sapiens
Compartment: plasma membrane
Primary external reference: UniProt: PCSK6: P29122
Identifier: R-HSA-3009047
Species: Homo sapiens
Compartment: Golgi lumen
Primary external reference: UniProt: PCSK6: P29122
Identifier: R-HSA-6784630
Species: Homo sapiens
Compartment: extracellular region
Primary external reference: UniProt: PCSK6: P29122

Set (1 results from a total of 1)

Identifier: R-HSA-6784618
Species: Homo sapiens
Compartment: extracellular region

Reaction (3 results from a total of 3)

Identifier: R-HSA-6784628
Species: Homo sapiens
Compartment: plasma membrane, extracellular region
LPL enzyme is catalytically active as a dimer composed of two glycosylated subunits of LPL connected in a head-to-tail arrangement by non-covalent interactions. Dimeric LPL is cleaved by several proprotein convertases. FURIN and proprotein convertase subtilisin/kexin type 6 (PCSK6 aka PACE4) can cleave LPL dimer, inactivating it, resulting in subsequent increase in plasma TG concentrations (Siezen et al. 1994, Bassi et al. 2000, Jin et al. 2005). Endogenous modulators of LPL are the angiopoietin-like proteins ANGPTL3 and ANGPTL4, which can bind transiently to LPL dimer, resulting in conversion of the enzyme from a catalytically active dimer to inactive, but still folded, monomers (Liu et al. 2010, Sukonina et al. 2006). ANGPTL4 regulates plasma triglyceride concentration via the inhibition of LPL (Dijk & Kersten 2014). GWAS studies (Dewey et al. 2016, MIG and CARDIoGRAM Consortium 2016) show a strong correlation between inactivating ANGPTL4 mutants and lower levels of triglycerides and lower risk of coronary artery disease than non-carriers. Therapeutic modulation of ANGPTL4 could be a new strategy against dyslipidemia (Kersten 2016).
Identifier: R-HSA-8849797
Species: Homo sapiens
Compartment: plasma membrane, cytosol
Filaggrin is initially synthesized as a large, insoluble, highly phosphorylated precursor containing many tandem copies of 324 residues. This precursor is dephosphorylated and proteolytically cleaved by several proteases, including the undefined protease PEP1 (Resing et al. 1996), mu-calpain (Yamazaki et al. 1997), furin, PCSK6 (PACE4) (Pearton et al. 2001), PRSS8 (cap1) (Leyvraz et al. 2005), ST14 (matriptase) (List et al. 2003), CELA2 (Bonnart et al. 2010), CASP14 (Denecker et al. 2007) and Kallikrein-related peptidase 5 (KLK5) (Sakabe et al. 2013). Filaggrin is further processed and proteolytically degraded by CASP14 (Eckhart & Tschachler 2011).
Identifier: R-HSA-8934819
Species: Homo sapiens
Compartment: cytosol
Filaggrin is initially synthesized as a large, insoluble, highly phosphorylated precursor containing many tandem copies of 324 residues. This precursor is dephosphorylated and proteolytically cleaved by several proteases, including the undefined protease PEP1 (Resing et al. 1996), mu-calpain (Yamazaki et al. 1997), furin, PCSK6 (PACE4) (Pearton et al. 2001), PRSS8 (cap1) (Leyvraz et al. 2005), ST14 (matriptase) (List et al. 2003), CELA2 (Bonnart et al. 2010), CASP14 (Denecker et al. 2007) and Kallikrein-related peptidase 5 (KLK5) (Sakabe et al. 2013). Filaggrin is further processed and proteolytically degraded by CASP14 (Eckhart & Tschachler 2011).
Cite Us!